Cancers,
Год журнала:
2025,
Номер
17(5), С. 765 - 765
Опубликована: Фев. 24, 2025
Background/Objectives:
The
treatment
of
older
patients
with
classic
Hodgkin
lymphoma
(eHL)
remains
a
challenge.
Methods:
This
study
reports
the
first
real-life
survey
eHL
treated
contemporary
therapies
in
Italy.
One
hundred
and
fifty
were
between
2013
2018:
seventy-one
aged
60-69
years
seventy-nine
≥70
(median
age
70.5
years;
range
=
60-89).
Curative
treatments
included
ABVD-like
regimens
attenuated
approaches
alternating
non-anthracycline-containing
cycles.
Results:
After
median
follow-up
81
months,
5-year
overall
survival
(OS)
was
87%
for
62%
those
≥70.
Among
132
(88%)
curative
intent,
cancer-specific
(CSS)
93%
group
70%
group,
while
event-free
(EFS)
78%
58%,
respectively
(p
<
0.001).
Multivariate
analysis
showed
that
≥
70,
omission
radiotherapy
(RT),
failure
to
achieve
complete
remission
(CR)
after
chemotherapy
significant
predictors
OS,
CSS,
EFS.
Synthetic
data
confirmed
omitting
RT
worsens
outcomes
at
all
stages,
reduced-dose
anthracycline
are
non-inferior
full-dose
schedules.
Conclusions:
highlights
key
prognostic
factors
supports
optimization
future
strategies
including
targeted
drugs.
Progress in Biomedical Engineering,
Год журнала:
2023,
Номер
5(4), С. 042002 - 042002
Опубликована: Окт. 1, 2023
Abstract
Randomized
clinical
trials,
while
often
viewed
as
the
highest
evidentiary
bar
by
which
to
judge
quality
of
a
medical
intervention,
are
far
from
perfect.
In
silico
imaging
trials
computational
studies
that
seek
ascertain
performance
device
collecting
this
information
entirely
via
computer
simulations.
The
benefits
in
for
evaluating
new
technology
include
significant
resource
and
time
savings,
minimization
subject
risk,
ability
study
devices
not
achievable
physical
world,
allow
rapid
effective
investigation
technologies
ensure
representation
all
relevant
subgroups.
To
conduct
digital
representations
humans
needed.
We
review
latest
developments
methods
tools
obtaining
studies.
First,
we
introduce
terminology
classification
human
models.
Second,
survey
available
methodologies
generating
with
healthy
diseased
status
examine
briefly
role
augmentation
methods.
Finally,
discuss
trade-offs
four
approaches
sampling
cohorts
associated
potential
bias
selecting
specific
patient
distributions.
AI and Ethics,
Год журнала:
2025,
Номер
5(3), С. 3241 - 3254
Опубликована: Янв. 10, 2025
Synthetic
data
are
increasingly
being
used
in
data-driven
fields.
While
synthetic
is
a
promising
tool
medicine,
it
raises
new
ethical,
legal,
and
social
implications
(ELSI)
challenges.
There
recognized
need
for
well-designed
approaches
standards
documenting
communicating
relevant
information
about
artificial
intelligence
(AI)
research
datasets
models,
including
consideration
of
the
many
ELSI
This
study
investigates
ethical
dimensions
explores
utility
challenges
ELSI-focused
computational
checklists
biomedical
AI
via
semi-structure
interviews
with
subject
matter
experts.
Our
results
suggest
that
experts
have
tempered
views
promises
both
checklists.
Experts
discussed
number
issues
covered
by
previous
literature
on
topic,
such
as
bias
privacy,
yet
other
less
issues,
justice
trust
were
also
raised.
When
discussing
our
participants
highlighted
connected
to
developing
implementing
them.
Research Square (Research Square),
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 13, 2025
Abstract
Tacrolimus,
commonly
used
after
organ
transplantation,
has
a
narrow
therapeutic
index
(NTI)
and
high
risk
of
dosing
errors,
with
over
50%
patients
suffering
serious,
potentially
life-threatening
adverse
effects.
To
address
this,
we
developed
an
interpretable
long
short-term
memory
(LSTM)
model
trained
on
14
years
data
from
1,774
across
Spain
the
United
States.
This
LSTM
predicts
tacrolimus
levels
using
clinical
data,
approximately
5%
mean
absolute
error,
outperforming
state-of-the-art
models.
Addressing
privacy
concerns,
demonstrate
that
synthetic
can
replace
real
for
training
without
performance
loss.
Finally,
launched
dosetailor.com,
platform
providing
personalised
recommendations
clinicians.
Although
focused
tacrolimus,
this
forms
foundation
personalising
dosage
high-risk,
NTI
drugs.
Cancers,
Год журнала:
2025,
Номер
17(5), С. 765 - 765
Опубликована: Фев. 24, 2025
Background/Objectives:
The
treatment
of
older
patients
with
classic
Hodgkin
lymphoma
(eHL)
remains
a
challenge.
Methods:
This
study
reports
the
first
real-life
survey
eHL
treated
contemporary
therapies
in
Italy.
One
hundred
and
fifty
were
between
2013
2018:
seventy-one
aged
60-69
years
seventy-nine
≥70
(median
age
70.5
years;
range
=
60-89).
Curative
treatments
included
ABVD-like
regimens
attenuated
approaches
alternating
non-anthracycline-containing
cycles.
Results:
After
median
follow-up
81
months,
5-year
overall
survival
(OS)
was
87%
for
62%
those
≥70.
Among
132
(88%)
curative
intent,
cancer-specific
(CSS)
93%
group
70%
group,
while
event-free
(EFS)
78%
58%,
respectively
(p
<
0.001).
Multivariate
analysis
showed
that
≥
70,
omission
radiotherapy
(RT),
failure
to
achieve
complete
remission
(CR)
after
chemotherapy
significant
predictors
OS,
CSS,
EFS.
Synthetic
data
confirmed
omitting
RT
worsens
outcomes
at
all
stages,
reduced-dose
anthracycline
are
non-inferior
full-dose
schedules.
Conclusions:
highlights
key
prognostic
factors
supports
optimization
future
strategies
including
targeted
drugs.
